APA

Curtis N. J., Mooney L., Hopcroft L., Michopoulos F., Whalley N., Zhong H., Murray C., Logie A., Revill M., Byth K. F., Benjamin A. D., Firth M. A., Green S., Smith P. D. & Critchlow S. E. (2017). Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. : Oncotarget.

Chicago

Curtis Nicola J, Mooney Lorraine, Hopcroft Lorna, Michopoulos Filippos, Whalley Nichola, Zhong Haihong, Murray Clare, Logie Armelle, Revill Mitchell, Byth Kate F, Benjamin Amanda D, Firth Mike A, Green Stephen, Smith Paul D and Critchlow Susan E. 2017. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. : Oncotarget.

Harvard

Curtis N. J., Mooney L., Hopcroft L., Michopoulos F., Whalley N., Zhong H., Murray C., Logie A., Revill M., Byth K. F., Benjamin A. D., Firth M. A., Green S., Smith P. D. and Critchlow S. E. (2017). Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. : Oncotarget.

MLA

Curtis Nicola J, Mooney Lorraine, Hopcroft Lorna, Michopoulos Filippos, Whalley Nichola, Zhong Haihong, Murray Clare, Logie Armelle, Revill Mitchell, Byth Kate F, Benjamin Amanda D, Firth Mike A, Green Stephen, Smith Paul D and Critchlow Susan E. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. : Oncotarget. 2017.